Emerging Regenerative Approaches for Periodontal Regeneration: The Future Perspective of Cytokine Therapy and Stem Cell Therapy by unknown
135© The Author(s) 2017 
K. Sasaki et al. (eds.), Interface Oral Health Science 2016, 
DOI 10.1007/978-981-10-1560-1_12
 Chapter 12 
 Emerging Regenerative Approaches 
for Periodontal Regeneration: The Future 
Perspective of Cytokine Therapy and Stem 
Cell Therapy 
 Shinya  Murakami 
 Abstract  Cytokine therapy using basic fi broblast growth factor (FGF-2) has 
attracted attention as a next-generation periodontal tissue regenerative therapy. 
Clinical trial studies to date have shown that local application of 0.3 % FGF-2 
induces statistically signifi cant new alveolar bone formation. In vitro analyses using 
cultured periodontal ligament cells showed that FGF-2 maintains stem cells in an 
undifferentiated state and promotes the proliferation of these stem cells during the 
initial stages of wound healing. This increases the cell density of periodontal tissue 
stem cells at the site of healing, promotes angiogenesis, and produces specifi c extra-
cellular matrix molecules, thereby preparing a local environment suitable for the 
regeneration of periodontal tissue. Additionally, based on an analysis in beagles, 
when adipose tissue-derived multi-lineage progenitor cells (ADMPCs) isolated 
from adipose tissue were transplanted together with fi brin gel to areas of periodon-
tal tissue loss, signifi cant regeneration of periodontal tissue was observed at the 
transplantation site. These results strongly suggest that adipose tissue, which is 
abundant in the human body and can be easily and safely collected, is a promising 
source of stem cells to promote the regeneration of periodontal tissue. 
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12.1  Introduction 
 Periodontal disease occurs when a bacterial biofi lm (dental plaque) adheres to the 
boundary between the teeth and gingiva, causing chronic infl ammation and progres-
sively destroying the periodontal tissue that supports the teeth. Therefore, periodon-
tal treatment involves scaling and root planing, which mechanically removes the 
causative bacteria biofi lm together with the necrotic cementum from the surface of 
the tooth root. Appropriate application of this therapy eliminates periodontal tissue 
infl ammation and stops the process of destruction of the same tissue. However, 
removing the cause of the disease does not regenerate the lost periodontal tissue to 
its original state. Given the high prevalence of periodontal disease both in Japan and 
worldwide and the need to maintain or enhance “QOL supported by the teeth and 
the mouth” in middle-aged and elderly people, developing highly predictable peri-
odontal tissue regenerative therapy that can be performed as a follow-on after treat-
ment to remove the cause is urgently needed. 
12.2  Periodontal Ligament as a Storage Site for Periodontal 
Tissue Stem Cells 
 Induction of tissue regeneration requires the presence of stem cells. Studies of 
regenerative medicine for periodontal tissue have shown that tissue stem cells that 
make the regeneration of periodontal tissue possible are present in the tissue sur-
rounding the tooth root, known as the periodontal ligament, even in adults. The 
periodontal ligament is a ligament tissue located between the cementum and alveo-
lar bone, with a thickness of 100–200 μm. Type I collagen fi ber bundles form the 
main body of the periodontal ligament; the principal cellular components of this 
tissue include the periodontal ligament fi broblasts as well as characteristic cell 
groups such as osteoblasts and osteoclasts on the surface of alveolar bone and 
cementoblasts found on the cementum surface. Interestingly, the results of various 
molecular biological analyses of periodontal ligament tissue show that many of the 
cells in the periodontal ligament show consistently high expression of molecules 
such as RUNX-2 and alkaline phosphatase which are closely associated with cyto-
differentiation into hard tissue-forming cells. These results suggest that the peri-
odontal ligament is involved in remodeling hard tissues such as alveolar bone and 
cementum depending on environmental changes. Furthermore, undifferentiated 
mesenchymal stem cells, which can differentiate into a variety of cell types other 
than osteoblasts and cementoblasts, are present in the human periodontal ligament 
[ 1 ,  2 ]. 
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12.3  Concept and Current Status of Periodontal Tissue 
Regenerative Therapy 
 Although mesenchymal stem cells that can differentiate into osteoblasts and 
cementoblasts are present in the adult periodontal ligament, periodontal tissue does 
not successfully regenerate when conventional periodontal treatment is performed 
to remove the cause of periodontal disease. Thus, in addition to conventional treat-
ment, it is necessary to develop a method for inducing the periodontal tissue stem 
cells present in the periodontal ligament. 
 The specifi c biological processes required for the regeneration of periodontal tis-
sue can be summarized into the following three processes: (1) selective and preferen-
tial induction of periodontal ligament-derived cells on the tooth root surface facing the 
areas of periodontal tissue loss, (2) proliferation and migration of undifferentiated 
mesenchymal stem cells (periodontal tissue stem cells) contained within the periodon-
tal ligament-derived cells while retaining their differentiation potential and then 
achieving site-specifi c differentiation as hard tissue-forming cells (osteoblasts and 
cementoblasts) and periodontal ligament fi broblasts, and (3) collagen fi ber bundles 
produced by periodontal ligament fi broblasts becoming embedded into bone tissue 
and cementum newly formed by osteoblasts and cementoblasts, resulting in regenera-
tion of the fi brous connections between the teeth and alveolar bone (Fig.  12.1 ).








 Fig. 12.1  Cellular and molecular basis of periodontal tissue regeneration. Periodontal tissue stem 
cells, including undifferentiated mesenchymal stem cells, are present in the periodontal ligament, 
and regeneration of periodontal tissue can be achieved by activating these cells to proliferate, 
migrate, and site specifi cally differentiate at the site of periodontal tissue loss 
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 Periodontal tissue regenerative therapies with clinical applications have been 
developed previously, including the “guided tissue regeneration method” and 
“enamel matrix protein method.” These treatment methods have a long history of 
use in dental practice and have shown some degree of success. However, there are a 
number of issues remaining related to indicated conditions and predictability, and 
improvements to these methods are required. Therefore, the action mechanism 
should be determined and next-generation periodontal tissue regenerative therapy 
with stable predictability should be established. 
12.4  Possibility of Cytokine Therapy 
 Human recombinant cytokines are currently used as therapeutic agents in a variety 
of diseases. In the fi eld of periodontal tissue regenerative medicine, there have been 
many attempts to induce regeneration of periodontal tissue through the migration of 
periodontal tissue stem cells to the site of periodontal tissue loss and proliferation of 
these cells in the same area or differentiation to osteoblasts and cementoblasts, 
which are activated through local application of specifi c cytokines. 
 In the USA, a combination of platelet-derived growth factor (PDGF) and 
β-tricalcium phosphate (β-TCP) (β-TCP + 0.3 mg/mL PDGF) has been approved by 
the US Food and Drug Administration (FDA) to induce regeneration of periodontal 
tissue, which is marketed as GEM21S®. Cytokines are also applied in dentistry 
using a combination of bone morphogenic protein-2 (BMP-2) and bovine type I 
collagen, which has also been approved by the US FDA as a medical device used in 
alveolar ridge augmentation procedures and sinus elevation surgery. Thus, human 
recombinant cytokines are beginning to be applied in the fi eld of dentistry. 
12.5  Inducing Periodontal Tissue Regeneration with Basic 
Fibroblast Growth Factor (FGF-2) 
 Fibroblast growth factors (FGFs) are a group of proteins that promote fi broblast 
proliferation and were discovered in the brain and pituitary gland tissue. This family 
of proteins comprises FGF-1 to FGF-23. Among these, FGF-2 induces the prolif-
eration of a wide variety of cells, including fi broblasts, vascular endothelial cells, 
neuroectodermal system cells, osteoblasts, chondrocytes, vascular smooth muscle 
cells, and epithelial cells. FGF-2 has attracted attention in the fi eld of regenerative 
medicine because: (1) FGF-2 has potent angiogenesis-promoting action and (2) 
FGF-2 promotes the cellular proliferation of undifferentiated mesenchymal cells 
while retaining their pluripotency. An example of the clinical application of FGF-2 
is as a therapeutic agent for intractable skin ulcers, such as decubital ulcers, and this 
therapy has been approved for manufacture in Japan. 
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 In our laboratory, we verifi ed the effi cacy and safety and determined whether 
FGF-2 promotes the regeneration of periodontal tissue in animal studies [ 3 ,  4 ]. We 
experimentally prepared class II furcation involvement at the furcation sites of man-
dibular molars in beagles and nonhuman primate and fi lled the bone defect, on the 
experimental side, with 0.1–0.4 % FGF-2 with a gelatinous carrier and measured the 
histological morphology at 6 and 8 weeks after FGF-2 administration. The results 
showed that regeneration of periodontal tissue was associated with a statistically 
signifi cant increase in new bone volume, new trabecular bone volume, and new 
cementum volume and was induced by local administration of FGF-2 (Fig.  12.2 ). 
At the same site, we observed the reappearance of Sharpey’s fi bers and rebuilding 
of fi brous attachments [ 3 ]. Extension of the peripheral nerves and Ruffi ni nerve 
endings was detected in the regenerated periodontal ligament. This strongly sug-
gests that local administration of FGF-2 not only constructs periodontal tissue but 
also regenerates the function of sensory receptors in the tissue.
 Furthermore, abnormal healing fi ndings such as downgrowth of the gingival epi-
thelium, ankylosis, and root resorption were not detected in cases on the side admin-
istered FGF-2. 
 We conducted an early phase II (PIIa) clinical trial (double-blind study with 
dose-response concurrent control, including placebo) with 13 participating facilities 
throughout Japan to investigate whether FGF-2 could induce the regeneration of 
periodontal tissue as well as the safety of FGF-2 (2002–2004). In this study, we 
investigated the effi cacy and safety of FGF-2 as a drug to induce the regeneration of 
periodontal tissue using a placebo (3 % hydroxypropylcellulose, which was used as 
the carrier) and the investigational drug containing 0.03 %, 0.1 %, and 0.3 % FGF-2. 
The results revealed a statistically signifi cant induction of new alveolar bone forma-
tion based on standardized x-ray images after local administration of 0.3 % FGF-2 
to human 2- or 3-wall intrabony defects in the alveolar bone [ 5 ]. Next, we imple-
mented a late phase II (PIIb) clinical trial (dose-response study) with 24 participat-
ing facilities throughout Japan to investigate the effi cacy and safety of FGF-2 using 
placebo and the investigational drug containing 0.2 %, 0.3 %, and 0.4 % FGF-2 
(2005–2007). The results showed that all investigational drugs containing FGF-2 
induced statistically signifi cant new alveolar bone formation, and 0.3 % FGF-2 was 
the clinically recommended dose [ 6 ] (Fig.  12.2a ). Based on these results, we then 
implemented a phase III (PIII) clinical study (randomized double-blind parallel- 
group comparison study) with 23 participating facilities throughout Japan to inves-
tigate the effi cacy and safety of FGF-2 using placebo and the investigational drug 
containing 0.3 % FGF-2 (2008–2010). The results confi rmed that the investigational 
drug containing 0.3 % FGF-2 signifi cantly increased alveolar bone ( p < 0.001) (Fig. 
 12.2b ) [ 7 ]. Additionally, no cases throughout the entire clinical study period were 
problematic in terms of safety. 
 We conducted detailed investigations into the effect of FGF-2 on cultured human 
periodontal ligament-derived cells to elucidate the mechanism of FGF-2-induced 
periodontal tissue regeneration; we predict the action mechanism to be as follows 
(Fig.  12.3 ). First, during the initial stages of wound healing, FGF-2 promotes the 
proliferation of stem cells while retaining their undifferentiated state and increases 
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the cell density of periodontal tissue stem cells at the wound site. Furthermore, 
FGF-2 promotes angiogenesis and the production of specifi c extracellular matrix 
molecules, creating a suitable local environment for the regeneration of periodontal 
tissue. After the effect of the locally administered FGF-2 is removed from the 
administration site through degradation or other actions, the periodontal tissue stem 
cells, which had increased in number, begin to differentiate into hard tissue-forming 
cells in the optimal environment created by FGF-2 administration. This promotes 
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 Fig. 12.2  Rate of increase in the height of alveolar bone 9 months after FGF-2 administration 
(clinical trial results on effi cacy). ( a ) Late phase II clinical study: The subjects were divided into 
four groups (placebo group and 0.2 %, 0.3 %, and 0.4 % FGF-2 treatment groups); each investiga-
tional drug was administered under double-blinded conditions. The fi gure shows the digitized 
results of a standardized dental x-ray taken 9 months after administration of the investigational 
drug and shows the percentage of the depth of the intrabony defect prior to treatment that had been 
fi lled with new bone (Adapted from literature [ 6 ]). ( b ) Phase III clinical study: The subjects were 
divided into two groups (placebo group and 0.3 % FGF-2 treatment group); each investigational 
drug was administered under double-blinded conditions. The fi gure shows the digitized results of 
a standardized dental x-ray taken 9 months after administration of the investigational drug and 
shows the percentage of the depth of the intrabony defect compared to before treatment that had 




the regeneration of periodontal tissue, both in number and time period, including the 
formation of new alveolar bone and cementum [ 8 ].
12.6  Future Outlook of Cytokine Therapy Using FGF-2 
 The concept of “scaffold” has not been introduced for FGF-2 preparations, and 
clinical studies are currently underway. This is because the aim of both clinical stud-
ies was to fi rst clarify the effi cacy and safety of FGF-2 alone as a drug. However, in 
the next stage, we will examine tissue engineering-type methods for the FGF-2 
carrier. 
 To date, in animal experiments using a severe periodontal tissue loss model (one 
wall intrabony defect model), we have found that following administration of 0.3 % 
FGF-2 with β-TCP, there is no recession of the gingiva postoperatively and that 
signifi cant periodontal tissue regeneration is induced at the same loss site [ 9 ]. If a 
new carrier for FGF-2 preparation is developed that can retain the space (space- 
making) at which the regeneration of periodontal tissue is expected, and with the 
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 Fig. 12.3  Mechanism of induction of periodontal tissue regeneration with FGF-2. FGF-2 strongly 
promotes the migration and proliferation of immature human periodontal ligament (PDL) cells 
while retaining the cells’ differentiation potential and increases the number of periodontal tissue 
stem cells at the site of periodontal tissue loss. Furthermore, FGF-2 promotes the production of 
angiogenesis and various extracellular matrices at the administration site, creating a suitable local 
environment for “periodontal tissue regeneration” 
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appropriate formativeness and osteoconductive properties required by operators, the 
application of FGF-2 preparations is expected to be further broadened. Additionally, 
the results of animal experiments suggest that if the 0.3 % FGF-2 preparation is used 
concurrently during dental implant surgery, the healing time to achieve osseointe-
gration will be shortened and robust integration will be achieved; further verifi ca-
tion of these concepts is required in the future [ 10 ]. 
12.7  Possibility of Periodontal Tissue Regenerative Therapy 
with Stem Cell Transplantation 
 The periodontal tissue regenerative therapy described above promotes the regenera-
tion of periodontal tissue by inducing the functions of stem cells present in all peri-
odontal ligaments. However, the number of stem cells in periodontal ligament 
decreases with age [ 11 ]. Therefore, in elderly people and in cases of severe peri-
odontal disease, we do not expect an adequate amount of regeneration simply by 
activating the stem cells present in the periodontal ligament. In these cases, it may 
be necessary to promote periodontal tissue regeneration by transplanting mesenchy-
mal stem cells collected from other tissue in the same patient to the site of periodon-
tal tissue loss. 
 The use of induced pluripotent stem cells is expected in the future, but it will still 
be some time before this technology can be clinically applied in the fi eld of den-
tistry. However, it has been clarifi ed that undifferentiated mesenchymal stem cells 
are present in a variety of tissues in our bodies, even after reaching adulthood. 
Studies are currently being conducted to regenerate periodontal tissue by transplant-
ing stem cells collected from these tissues into the site of periodontal tissue loss 
together with suitable scaffolding materials. 
 Examples of bone marrow cells used to regenerate periodontal tissue are as fol-
lows. There is a report showing that mixing bone marrow cells collected from the 
ilium or other such sites with platelet-rich plasma and transplanting the mixture into 
the site of periodontal tissue loss is effective for inducing periodontal tissue regen-
eration [ 12 ], whereas another report found that after stimulating and proliferating 
collected bone marrow cells with FGF-2 in the laboratory, subsequent mixing the 
cells with collagen gel as scaffolding material promotes periodontal tissue regenera-
tion [ 13 ]. In these cases, undifferentiated mesenchymal cells and osteoblast pro-
genitor cells in the bone marrow were used as stem cell sources during periodontal 
tissue regeneration. 
 Another study investigated the promotion of periodontal tissue regeneration by 
collecting tissue slices from the maxilla periosteum, culturing the cells collected 
from the same tissue slice (periosteum-derived cells: expected to be cells with high 
osteogenic potential) in a sheet format, and transplanting the cultured cells together 
with platelet-rich plasma and hydroxyapatite into the site of periodontal tissue loss; 
this process stimulated new alveolar bone formation and promoted regeneration 
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[ 14 ]. Furthermore, another study investigated culturing periodontal ligament cells 
in a sheet format, transplanting the cells onto the surface of a tooth root that had 
been exposed at the site of periodontal tissue loss, and transplanting β-TCP at the 
site of bone loss for total regeneration of periodontal tissue [ 15 ]. 
 In our laboratory, we focused on adipose tissue, which we consider to be less of 
a burden on the patient during collection and a safer tissue. We investigated the use 
of undifferentiated mesenchymal stem cells present in another tissue as a source of 
stem cells (Fig.  12.4 ). We previously reported that adipose tissue-derived multi- 
lineage progenitor cells (ADMPCs) collected using our method differentiate into 
osteoblasts, myocardial cells, liver cells, and insulin-producing cells, as ADMPCs 
are pluripotent [ 16 – 19 ]. We also confi rmed in in vitro that ADMPC isolated from 
human adipose tissue can differentiate into osteoblasts and periodontal ligament 
cells. Next, we investigated the effect of inducing periodontal tissue regeneration by 
ADMPC transplantation in a beagle periodontal disease model. We created artifi cial 
periodontal tissue loss (class II furcation involvement) at the furcation site of the 
fourth premolars in beagles and transplanted ADMPC isolated from adipose tissue 
collected from the abdominal area together with fi brin gel into the same site of the 
defect. The results confi rmed signifi cant regeneration of periodontal tissue at the 
transplantation site [ 20 ]. Interestingly, ADMPC had a remarkable trophic effect; 
insulin-like growth factor binding protein 6, which was secreted from ADMPC in 
large quantities, promoted the differentiation of periodontal tissue stem cells [ 21 ]. 
These results strongly suggest that adipose tissue, which is abundant in the body and 
Adipose
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 Fig. 12.4  Periodontal regeneration by transplantation of ADMPC. Approximately 30 mL of 
abdominal adipose tissue was suction sampled from the patient with periodontal disease, and 
ADMPCs were collected from the same tissue in the Cell Processing Center. These cells were then 
cultured until a suffi cient volume of ADMPCs was acquired, which was then mixed with fi brin gel. 
Regeneration of periodontal tissue was induced by transplanting the same admixture into the site 
of the intrabony defect during periodontal surgery in the same patient 
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can be easily and safely collected, can be used as a source of stem cells to promote 
the regeneration of periodontal tissue.
12.8  Conclusion 
 Periodontal tissue is a complex tissue comprised of alveolar bone, cementum, peri-
odontal ligament, and gingiva, and the end target is to regenerate each type of tissue 
at will depending on the extent of periodontal tissue destruction. In the future, after 
ensuring the safety of this therapy, optimal scaffolding material can be customized 
for periodontal tissue regeneration to support stem cell migration and proliferation, 
as well as differentiation into osteoblasts and cementoblasts. The application of 
cytokine therapy using FGF-2 and periodontal tissue regenerative therapy through 
stem cell transplantation of ADMPC will not be restricted to the fi eld of dentistry, 
but can also be expanded to other medical fi elds. Additionally, in the near future, we 
hope to establish patient-specifi c periodontal tissue regenerative therapy by com-
bining optimal conditions with cytokines, stem cells, and scaffolding materials. 
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